将精准医学纳入儿科肿瘤学有望对未来癌症儿童的治疗方式产生积极影响。尽管有许多针对儿童癌症的精准医学研究，但关于实施相关测试的成本的证据有限。这是澳大利亚第一项通过“零儿童癌症精准医疗计划”系统地衡量使用精准医疗治疗高危儿童癌症的成本的研究。以 2021 年澳元计算，包括基因组和临床前测试在内的估计成本为： (A) 每位患者的访问费用为 12,743 美元； (B) 每次分子原因鉴定 14,262 美元； (C) 每个 MTB 建议 21,769 美元。获得的信息有助于理解报告与肿瘤生物学、诊断、预后相关的临床重要结果以及可能改善儿童临床管理的成本。© 2024。作者。

Embedding precision medicine in paediatric oncology shows promise to have a positive impact on how children with cancer will be treated in the future. While there are a number of studies of precision medicine in childhood cancer, there is limited evidence available on the cost of implementing the related testing. This is the first Australian study that systematically measures the cost of using precision medicine in the care of high-risk childhood cancers, through the Zero Childhood Cancer Precision Medicine Programme. In 2021 Australian dollars, the estimated costs inclusive of genomic and preclinical testing were: (A) $12,743 per patient for access; (B) $14,262 per identification of molecular cause; and (C) $21,769 per MTB recommendation. The information gained supports the understanding of the cost of reporting clinically significant outcomes relevant to the biology of the tumour, diagnosis, prognosis and potentially improving clinical management for a child.© 2024. The Author(s).